Clinical Trial Update: Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Sintilimab plus R-CHOP in treatment-naive EBV-positive DLBCL, NOS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebv-positive Diffuse Large B-cell Lymphoma Not Otherwise Specified

Drugs mentioned

• R-CHOP
• Sintilimab (sintilimab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: EBV-Positive DLBCL, Nos | Phase 2 | Status: UNKNOWN